

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2017

Rs. In Lakhs

Particulars	Quarter Ended			Year to date	Year to date
	31-Dec-2017	30-Sep-2017	31-Dec-2016	figures for the	figures for the
	(Unaudited)	(Unaudited)	(Unaudited)	Current Period	Previous Period
				Ended	Ended
				31-Dec-2017	31-Dec-2016
				(9 Months)	(9 Months)
				(Unaudited)	(Unaudited)
I. Revenue from Operations (Gross)	1,581.61	832.00	2,501.03	3,145.70	6,495.02
II. Other Income	60.05	69.49	9.26	158.12	73.69
III. Total Revenue (I+II)	1,641.66	901.49	2,510.29	3,303.82	6,568.71
IV. Expenses					
(a) Cost of Materials Consumed	659.72	452.40	797.09	1,395.06	2,492.98
(b) Purchase of traded goods	16.58	9.66	130.85	101.48	293.00
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	79.28	12.47	41.28	89.79	17.79
(d) Excise Duty	-	-	164.12	81.00	505.39
(e) Employee benefits expense	267.31	321.23	259.83	809.46	739.34
(f) Finance Costs	139.04	422.09	448.30	984.33	1,221.35
(g) Depreciation and amortisation expense	158.10	157.59	123.97	455.00	368.33
(h) Other expenses	223.81	440.30	314.01	964.12	1,006.51
Total expenses	1,543.84	1,815.74	2,279.45	4,880.24	6,644.69
V. Profit/(Loss) before Exceptional Items and Taxes (III - IV)	97.82	(914.25)	230.84	(1,576.42)	(75.98)
VI. Exceptional Items (Net)	-	-	181.13	-	181.13
VII. Profit/(Loss) before Tax (V - VI)	97.82	(914.25)	49.71	(1,576.42)	(257.11)
VIII. Tax Expenses	(5.38)	(24.25)	(18.78)	(37.21)	65.10
IX. Profit/(Loss) for the period (VII + VIII)	103.20	(890.00)	68.49	(1,539.21)	(192.01)
X. Other Comprehensive Income	(1.39)	(1.39)	(1.39)	(4.17)	(4.16)
XI. Total Comprehensive Income (IX + X)	101.81	(891.39)	67.10	(1,543.38)	(196.17)
XII. Paid up Equity Share Capital (face value Rs.10/- per share)	2,814.00	2814.00	2,204.00	2,814.00	2,204.00
Earnings Per Share of Rs 10/-each (not annualised)					
(a) Basic	0.36	(3.79)	1.04	(5.93)	(0.36)
(b) Diluted	0.36	(3.79)	1.04	(5.93)	(0.36)





Contd...2/-..

Notes :

1. The above unaudited financial results as reviewed by the Audit Committee, have been approved and taken on record at the meeting of the Board of Directors held on 12th February, 2018. The limited review as required as per listing agreement has been carried out by the Statutory Auditors of the Company.
2. The Company has adopted Indian Accounting Standards ("Ind AS") notified by the Ministry of Corporate Affairs w.e.f. 1st April, 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 – "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
3. The Company has applied to two of its banks for settlement of principal / interest amount. The management has accordingly not provided for interest on such loans for the quarter ending 31st December, 2017 amounting to Rs.281.23 lakhs
4. Pursuant to the approval of merger between Lyka Labs Limited with Lyka Healthcare Limited by the Board of Directors in its Board Meeting held on 29th May, 2017. Subsequently, NCLT, Ahmedabad bench has delivered an order 6th February, 2018 for holding a meeting with its Equity and Preference Share holder, Secured and Unsecured Creditors on 27th March, 2018 for the approval of the proposed scheme of merger.
5. The reconciliation of net loss reported for the quarter and Nine months ended 31st December, 2016 in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below :

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended 31 st December, 2016	Nine months ended 31 st December, 2016
a.	Net Profit/(Loss) as per Indian GAAP	106.93	(46.83)
b.	Fair value of financial liabilities/ Assets	11.51	27.71
c.	Fair value of financial Investments	2.15	1.77
d.	Incremental Depreciation on fair value for selective items of Property, Plant & Equipment	(31.19)	(93.57)
e.	Employee benefits – actuarial loss on defined benefit plan reclassified to Other Comprehensive Income (OCI)	1.39	4.16
f.	Expected credit loss on financial assets	(37.18)	(133.46)
g.	Effect of Deferred Tax on above	18.78	65.10
h.	Net Profit /(Loss) before OCI as per Ind AS	68.47	(192.04)
i.	Other comprehensive income (OCI)	(1.39)	(4.16)
j.	Total Comprehensive income under Ind AS	67.09	(196.19)



6. The format for unaudited quarterly results as prescribed in SEBI's Circular CIR/CFB/CMD/15/2015 dt. Nov 30, 2015 has been modified to comply with the requirements of SEBI's circular dt. Jul 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013.
7. The Statement does not include Ind AS compliant results for the previous year ended March 31, 2017 as the same is not mandatory as per SEBI's circular dt. Jul 5, 2016.
8. These quarterly and nine month Financial Results may require adjustments before constituting the final Ind AS Financial statements as at and for the year ending March 31, 2018 due to changes in financial reporting requirements arising from new or revised standard or interpretation issued by MCA/appropriate authority or changes in the use of one more optional exemptions from full retrospective application of certain IndAS as permitted under IndAS 101.
9. Post the applicability of Goods and Service Tax (GST) w.e.f. July 1, 2017, revenue from operations is disclosed net of GST, accordingly, the revenue from operations and other expenses for the quarter/ nine months ended on December 31, 2017 are not comparable with the corresponding previous period figures.
10. As the Company's business activity falls within a single business segment viz. "Pharmaceuticals" and the sales substantially being in the domestic market, the financial statements are reflective of the information required by Ind AS 108.
11. The figures for previous period have been regrouped/ rearranged wherever considered necessary.

Mumbai
12th February, 2018



For LYKA LABS LIMITED

N. I. Gandhi (DIN 00021530)
(Chairman & Managing Director)